Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT05580861RecruitingPhase 1/Phase 2
Sulfasalazine for newly diagnosed AML in older adults on chemo
This Phase 1/2 trial studies whether sulfasalazine, added to intensive chemotherapy, can help older adults with newly diagnosed acute myeloid leukemia (AML). It aims to improve treatment effectiveness and track leukemia “leftover cells” in some participants.
AmiensAges 60 years+ - NCT06447090RecruitingPhase 2
VMAC plus donor cells for AML relapse after transplant
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05811845Recruiting
Testing blood monitoring of 6MP to help kids stay in remission
This trial is for children newly diagnosed with acute lymphoblastic leukemia (ALL). It tests whether checking medicine levels in the blood can help optimize ongoing treatment (maintenance) and potentially keep the cancer under control.
Monza, Monza BrianzaAges Up to 18 years - NCT06462248RecruitingPhase 2
CAR-T therapy for B-cell blood cancers
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
Hong KongAges 1 year+ - NCT07813390Enrolling by invitationPhase 2
New drug combo for leukemia that is no longer responding to venetoclax
This trial tests a combination of three drugs—homoharringtonine, lisaftoclax, and azacitidine—for people with acute myeloid leukemia (AML) whose cancer did not respond to or has returned after prior treatment with venetoclax. The goal is to see if this new combination can help control the leukemia when current options have failed.
Guangzhou, GuangdongAges 18 years+ - NCT07813208Recruiting
Treatment and survival of children with ph+ acute lymphoblastic leukemia
This study looks back at the diagnosis, treatment, and survival of children with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to understand how well standard treatments, including targeted therapy, work in these patients.
Hangzhou, ZhejiangAges 1 month–18 years - NCT06301425Recruiting
Transplant study for high-risk AML based on MRD response
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
BeijingAges 16–65 - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT07805096Recruiting
Smart health app for children with cancer and their parents
This study tests a smart health app designed to support the mental, physical, and spiritual well-being of children with leukemia or a brain tumor and their parents. It aims to see if the app helps improve overall health and quality of life.
TaipeiAges 7 years+ - NCT06536010Recruiting
Testing a new combination therapy for AML
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Huai'an, JiangsuAges 18–75 - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06554626RecruitingPhase 2
Study of blinatumomab and venetoclax followed by inotuzumab for B-ALL
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hangzhou, ZhejiangAges 40 years+ - NCT07774390Recruiting
Long-term outcomes of ibrutinib and venetoclax for CLL
This study looks at the long-term effects of taking ibrutinib and venetoclax together for chronic lymphocytic leukemia (CLL). It aims to see how well this treatment works over time and how it affects patients.
MilanAges Any age - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT06571825RecruitingPhase 4
Comparing transplant vs. venetoclax for older adults with AML
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
Hangzhou, ZhejiangAges 60–75 - NCT07761533RecruitingPhase 1/Phase 2
PBSS1113 plus azacitidine for blood cancers
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT07756034Recruiting
Cancer data registry for patients in the U.S.
This study collects information from people with cancer to help researchers learn more about the disease. You may join a general cancer registry or, if your child has a specific type of leukemia, a special part of the study.
Chicago, IllinoisAges Any age - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06598722RecruitingPhase 2
BCL-2 inhibitor plus HyperCVAD for T-cell lymphoma
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
ShanghaiAges 18–60
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.